Prisinformation från TradingView

Bolagspresentation:

Nyhetsflöde Acarix

Related articles:
4/12/2024 12:31:19 PM - Acarix: Influx of news ahead of Q1 - Redeye - Redeye leaves its comments following a few press releases from Acarix in the past few days. The news included adoption of a new business model, revising its financial targets, initiation of a US clinical study, and a new health economic analysis of CADScor presented at the ACC.
4/8/2024 5:19:27 AM - Acarix: Submitted application for cross-trading at OTCQB in the US - Redeye - Redeye has provided a brief comment on today's news regarding Acarix's submission of an application for cross-trading on OTCQB in the US. The press relerase is encouraging, as additional exposure to US-based investors could positively impact financing outlook and liquidity in the share.
2/19/2024 8:00:38 AM - Acarix Q4 2023: Soft ending to 2023 but gearing up for 2024 - Redeye - Redeye updates its outlook on Acarix following its year-end report 2023. Anticipating an eventful year head, we make minor adjustments to our forecasts and valuation.
2/2/2024 1:30:51 PM - Acarix: Uplifting news - Redeye - Redeye highlights two positive developments for Acarix: a SEK33.7m directed share issue and the inclusion of the CADScor system in the US Federal Supply Schedule. The nationwide contract simplifies the sales process for Acarix's most important customer the VA and other government agencies, further facilitating the US commercialization.
2/1/2024 1:00:04 PM - Acarix: New CEO announced - Redeye - Redeye leaves its comments on today's news that Acarix has appointed a new CEO.
11/13/2023 7:16:21 AM - Acarix Q3 2023: Soft sales but solid cost control - Redeye - Redeye makes minor changes to its estimates following Acarix’s Q3 2023 report, which featured lower sales and costs than we had anticipated. The company focuses on sales, and growth should take off in 2024 as contribution from the VA and IDN’s materialize.
11/9/2023 7:30:32 AM - Acarix Q3 2023: Softer sales but lower costs than estimated - Redeye - Redeye comments on Acarix's Q3 report which came in short of our estimates in terms of sales but due to lower costs loss was lower than expected on the EBIT level.
9/11/2023 2:38:33 PM - Acarix: SEK54m rights issue announced - Redeye - Redeye comments on Acarix and adjusts its valuation following the announcement of a SEK54m fully guaranteed rights issue.
9/4/2023 6:19:40 AM - Acarix Q2 2023: Soft sales but building foundation for growth - Redeye - Redeye considers Acarix’s Q2 2023 report soft in terms of sales, but we see a strong operational newsflow, establishing a solid foundation for a sales ramp-up moving into 2024.
5/23/2023 11:06:06 AM - Acarix: Warrant exercise and insiders increasing its equity - Redeye - Redeye comments on Acarix following the recent newsflow.
5/12/2023 7:14:28 AM - Acarix Q1 2023: Progress in the making - Redeye - Redeye leaves its comments on Acarix following the company’s Q1 2023 report. The report contained no significant surprises, and we largely maintain our fair value range.
5/11/2023 8:32:49 AM - Acarix Q1 2023: Initial comment - Redeye - Redeye leaves its comments on Acarix following its Q1 2023 report, which did not contain any major surprises. We will return shortly with a more elaborate research update.
5/11/2023 7:07:38 AM - Acarix Q1 2023: Initial comment - Redeye - Redeye leaves its comments on Acarix following its Q1 2023 report, which did not contain any major surprises. We will return shortly with a more elaborate research update.
4/5/2023 7:51:54 AM - Acarix: Uplifting News - Redeye - Redeye comments on Acarix following the near-term announcement of two uplifting press releases, including a SEK9.5m directed share issue and a strategic sales partnership expanding the company’s commercial reach with an additional 30 states.
2/22/2023 6:13:16 AM - Acarix: Breakthrough Order from VA - Redeye - Redeye welcomes today's news that Acarix has received an important "breakthrough" order from the US Veterans Health Administration (VA). The initial value of the order is cSEK1m, but it is expected to generate additional sales as the volume of patches accumulates over time. Additionally, we emphasize that this marks the first communicated order from the VA, which boosts confidence for potential future orders and presents a substantial commercial opportunity for Acarix. We reiterate our SEK0.7 base case.
1/13/2023 7:26:11 AM - Acarix: Gearing Up - Redeye - Redeye ups its near-term sales estimates and adjusts its fair value range for Acarix following steps forward on the US market and the recent capital injection. The partnership with the American College of Cardiology could prove to be an important piece of the puzzle, and we see eventful times in 2023 and 2024 for Acarix.
1/5/2023 7:07:00 AM - Acarix: Comments on rights issue and coverage resumed - Redeye - Redeye resumes its coverage and comments on the outcome of Acarix’s rights issue. We will return early next week with a more elaborate research update.
11/22/2022 8:01:25 AM - Acarix: Rights Issue Announced – We Pause Our Coverage - Redeye - Redeye briefly comments on Acarix's rights issue. We pause our coverage.
8/26/2022 5:51:40 AM - Acarix Q2: Steps In the Right Direction, Gross Margins Remains High - Redeye - Redeye leaves its comments on Acarix following the announcement of its Q2 report. Overall, we see promising steps forward in the US, and the company is laying ground for a growth journey in the coming years.
6/7/2022 5:45:50 AM - Acarix: Advancing in the US - Redeye - Redeye leaves its comments following today's news that Acarix has signed an additional agreement in the US and received orders from both Mississippi and Tennessee.
5/11/2022 11:04:06 AM - Acarix Q1’22: Our Comments - Redeye - Redeye leaves its comments on Acarix following the announcement of its year-end report.
2/21/2022 6:46:55 AM - Acarix: Capital Markets Day - Redeye - Company representatives from Acarix, including the new CEO, talk about the strategic plan, financial outlook, technology overview, and feedback from clinical users. Watch the replay from February 18.
2/17/2022 10:43:04 AM - Acarix Q4’21: Focus on the US - Redeye - Redeye leaves its view on Acarix following the announcement of its year-end report, which overall came in short of our estimates.
1/5/2022 9:20:25 AM - Acarix: Fair Value Range Adjustment - Redeye - Redeye adjusts its fair value range and resumes coverage of Acarix following the finalized rights issue.
11/5/2021 8:06:52 AM - Acarix: Rights Issue Announced – We Pause Our Coverage - Redeye - Redeye gives a short comment on the announced rights issue and pauses its coverage.
10/27/2021 11:48:26 AM - Acarix: CPT III Reimbursement Code Acquired - Redeye - Redeye leaves a comment following today’s positive news that Acarix has been granted a CPT III reimbursement code.
10/4/2021 9:38:16 AM - Acarix: Glimpsing the West - Redeye - Redeye reviews its assessment of Acarix, acknowledging the clinical and regulatory progress for the CADScor device and the catalysts ahead in the form of acquired reimbursement, high-volume orders, and establishment in the US market. We hike our fair value range as our reassessment suggests a more optimistic take on the case.
8/19/2021 11:30:33 AM - Acarix: Q2 – Paving The Way - Redeye - Redeye leaves a comment on Acarix following the release of its Q2 report. YoY sales show significant growth, and we expect an exciting time ahead for the company.
5/12/2021 6:07:28 AM - Acarix: Q1 Comments - Redeye - Redeye leaves a comment on Acarix following today’s announcement of the Q1 report.
1/13/2021 9:07:35 AM - Acarix får positiva preliminära resultat från hjärtsviktstudie - Diagnostikbolaget Acarix har fått positiva preliminära resultat från den undersökande Seismo-studien inom hjärtsvikt.
12/9/2020 9:22:51 AM - Sista patienten i Acarix studie Dan-NICAD II har inkluderats - Sista patienten i Acarix studie Dan-NICAD II har inkluderats. Data från sammanlagt 1 726 patienter har även skickats vidare till kranskärlsröntgen efter bedömt symtom på stabil kranskärlssjukdom. Det framgår av ett pressmeddelande.
11/26/2020 2:08:33 PM - Acarix erhåller unik enhetskod för CADScor av FDA - Acarix förmedlar att de erhållit en unik enhetskod av amerikanska läkemedelsverket FDA för sitt system CADScor. Den lyder "Coronary artery disease risk indicator using acoustic heart signals" och Acarix är det enda företaget med denna kod. Det framgår av ett pressmeddelande.
11/25/2020 12:21:35 PM - Acarix får marknadsgodkännande för Cadscor Systems för försäljning i USA - Acarix meddelar idag att det amerikanska läkemedelsverket FDA har godkänt bolagets De Novo ansökan för ett marknadsföringsgodkännande för Cadscor System i USA. Det framgår av ett pressmeddelande.
11/18/2020 9:13:53 AM - Resultat från analys av Acarix CADScor presenterades vid konferensen ISPOR - Acarix system CADScor presenterades idag vid den hälsoekonomiska konferensen ISPOR där positiva resultat från en jämförelseanalys uppvisades genom en poster. Det framgår av ett pressmeddelande.
11/17/2020 9:12:21 AM - Covid-19 har gett ett större intresse för Acarix teknik - vd - Medicinteknikbolaget Acarix teknik CADScor har sett ett större intresse efter covid-19-pandemin. Det förmedlar vd:n Per Persson under evenemanget Biostock Life Science Summit.
11/12/2020 7:16:58 AM - Acarix omsättning ökade i Q3 - Acarix redovisar en betydligt högre omsättning och mindre förlust i det tredje kvartalet, jämfört med året innan.
10/15/2020 2:04:07 PM - Redeye blir ny Certified Advisor för Acarix - Investmentbanken Redeye blir ny Certified Advisor för Acarix, från nuvarande Wildeco. Tillträde är den 19 oktober. Det framgår av ett pressmeddelande.
9/29/2020 11:13:56 AM - Acarix genomför riktad nyemission för garanter, utspädningseffekt på 2,3 procent - Acarix uppger att de genomför en riktad nyemission för garanterna från den tidigare företrädesemissionen till teckningskursen 0,712 kronor per aktie. Acarix erhåller ingen betalning för detta utan det sker genom kvittning av garanternas fordringar.
9/11/2020 11:22:31 AM - Slutligt utfall i Acarix nyemission i linje med preliminärt utfall - Acarix nyemission med företrädesrätt för aktieägarna tecknades till 123,2 procent och blev därmed övertecknad, enligt slutliga utfallet, vilket är i linje med det preliminära utfallet som meddelades i förrgår. Det framgår av ett pressmeddelande.
9/9/2020 6:07:46 AM - Acarix företrädesemission tecknades till 122 procent enligt preliminärt utfall - Diagnostikbolaget Acarix företrädesemission blev övertecknad med cirka 122 procent, enligt det preliminära utfallet. Det uppger bolaget i ett pressmeddelande.
9/3/2020 11:05:25 AM - Acarix går vidare med de tyska myndigheterna - Acarix meddelar att det tyska hälsovårdsministeriet har tillkännagivit att fonokardiografi för att utesluta kranskärlssjukdom har potential för allmän användning i Tyskland.
9/2/2020 6:26:06 AM - Acarix två största aktieägare överlåter teckningsrätter - förlänger teckningsperioden - Diagnostikbolaget Acarix har beslutat sig för att förlänga sin teckningsperiod i den pågående nyemissionen till den 8 september. Bakgrunden är att de två största ägarna Sunstone LSV Fund II K/S och SEED Capital DK II överlåtit sina teckningsrätter till ett antal investerare.
8/7/2020 6:19:18 AM - Acarix minskar omsättning men även rörelseförlusten under andra kvartalet - Acarix redovisar minskande omsättning under andra kvartalet jämfört med samma period året innan. Bolaget rapporterar även minskad förlust.
7/15/2020 6:18:01 AM - Acarix genomför företrädesemission på 56 miljoner kronor, garanterad till 90 procent - Acarix ska genomföra en företrädesemission som ger bolaget cirka 56 miljoner kronor före kostnader, enligt ett pressmeddelande.